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Abstract
Hypoxia activates endothelial cells by the action of reactive oxygen
species generated in part by cyclooxygenases (COX) production
enhancing leukocyte transmigration. We investigated the effect of
specific COX inhibition on the function of endothelial cells exposed
to hypoxia. Mouse immortalized endothelial cells were subjected to
30 min of oxygen deprivation by gas exchange. Acridine orange/
ethidium bromide dyes and lactate dehydrogenase activity were used
to monitor cell viability. The mRNA of COX-1 and -2 was amplified
and semi-quantified before and after hypoxia in cells treated or not
with indomethacin, a non-selective COX inhibitor. Expression of
RANTES (regulated upon activation, normal T cell expressed and
secreted) protein and the protective role of heme oxygenase-1 (HO-1)
were also investigated by PCR. Gas exchange decreased partial oxy-
gen pressure (PaO2) by 45.12 ± 5.85% (from 162 ± 10 to 73 ± 7.4
mmHg). Thirty minutes of hypoxia decreased cell viability and en-
hanced lactate dehydrogenase levels compared to control (73.1 ± 2.7
vs 91.2 ± 0.9%, P < 0.02; 35.96 ± 11.64 vs 22.19 ± 9.65%, P = 0.002,
respectively). COX-2 and HO-1 mRNA were up-regulated after hy-
poxia. Indomethacin (300 µM) decreased COX-2, HO-1, hypoxia-
inducible factor-1α and RANTES mRNA and increased cell viability
after hypoxia. We conclude that blockade of COX up-regulation can
ameliorate endothelial injury, resulting in reduced production of
chemokines.
Correspondence
N.O.S. Câmara
Laboratório de Imunologia Clínica
e Experimental
Divisão de Nefrologia, UNIFESP
Rua Botucatu, 740
04023-900 São Paulo, SP
Brasil
Fax: +55-11-5573-9652
E-mail: niels@nefro.epm.br
Research supported by CAPES and
FAPESP (Nos. 04/08311-6 and
04/13826-5).
Received August 19, 2005
Accepted May 31, 2006
Key words
• Endothelial cell
• Hypoxia
• Indomethacin
• Cyclooxygenase
• Heme oxygenase 1
Introduction
Acute renal failure, a clinical feature of
ischemia and reperfusion injury (IRI), re-
mains a major cause of morbidity and mor-
tality in hospitalized patients (1). In the trans-
plantation area, IRI is closely related to early
and long-term graft outcomes. Indeed, grafts
from recipients with delayed graft function
are more associated with chronic allograft
nephropathy and consequently with a re-
duced survival rate (2,3).
The cellular mechanisms involved in IRI
include ATP depletion, impaired calcium
regulation, generation of reactive oxygen
species (ROS), and the production of pro-
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inflammatory cytokines/chemokines. All
these mediators ultimately contribute to ac-
tivation of endothelial cells (4,5). Endotheli-
al cell activation is associated with pro-co-
agulant and pro-inflammatory phenotypes.
The up-regulation of class II molecules of the
major histocompatibility complex, together
with secretion of chemokines, promotes leu-
kocyte adhesion and further transmigration of
leukocytes through the endothelial barrier into
the tissue. Regulated upon activation, normal
T cell expressed and secreted (RANTES) pro-
tein is a key molecule involved in these events
which is secreted by endothelial cells and
activated leukocytes (6,7).
Cyclooxygenase (COX) is the key en-
zyme implicated in the generation of prosta-
glandins from arachidonic acid (8), a pro-
cess that promotes the generation of ROS
(9). Both isoforms, COX-1 and COX-2, par-
ticipate in the endothelial cell activation that
follows IRI (9,10). We have shown that
COX blockade in the murine model of IRI
leads to better organ function and preserves
the parenchymal architecture (11,12). The
mechanisms underlying this beneficial ef-
fect are not completely understood.
It has become apparent that the balance
between the injury factors and the tissue
responses that follow the initial damage is a
determinant of organ outcome. The tissue
can protect itself from injury by up-regulat-
ing a group of genes with anti-apoptotic and
anti-inflammatory properties, intended to
promote and maintain the physiological func-
tions of the organs. Heme oxygenase-1 (HO-
1) is one of the recently described protective
genes. The mechanisms underlying its role
are not clear, but probably rely on the ability
of this gene to protect endothelial cells from
undergoing apoptosis, to inhibit the pro-
inflammatory phenotype of activated mono-
cytes/macrophages, to promote vasodilata-
tion, to suppress platelet activation, and to
block smooth cell proliferation. These ef-
fects occur via generation of carbon monox-
ide, biliverdin and free iron, the end prod-
ucts of heme metabolism catalyzed by HO-1
(reviewed in Ref. 13). The enhanced HO-1
expression observed during hypoxia is due
to activation of the transcription factor, hy-
poxia-inducible factor (HIF)-1α. HIF-1α is
a heterodimeric peptide involved not only in
the sensing, but also in the adapting of cells
to changes in O2 levels. It is well established
that HIF-1 expression and activation corre-
late with tumor progression, cell apoptosis,
resistance to cancer treatment, and angio-
genesis (14-16).
On the basis of these considerations, we
hypothesize that the beneficial effects ob-
served with COX blockade in ischemic or-
gan injuries might be mediated in part by the
amelioration of the response of endothelial
cells to hypoxia. We addressed this question
by investigating the effect of specific COX
blockade (non-selective inhibition of COX-
1 and COX-2) in an in vitro model of gas-
eous hypoxia. We anticipated that pre-treat-
ment with indomethacin would promote bet-
ter endothelial cell viability and down-regu-
lation of COX-2 and RANTES messenger
RNA (mRNA) in the presence of hypoxia. In
addition, COX inhibition was also associ-
ated with a reduced expression of HO-1 and
HIF-1α gene transcripts under hypoxic con-
ditions.
Material and Methods
Cells
Mouse immortalized endothelial cells
were purchased from the American Type of
Culture Collection (ATCC, CRL-2167, Ma-
nassas, VA, USA) and cultivated in Dul-
becco’s modified Eagle’s medium (Gibco,
Carlsbald, CA, USA) supplemented with 5%
fetal bovine serum (Cultilab, Campinas, SP,
Brazil), HEPES, and penicillin/streptomy-
cin. All cultures were maintained in 25-cm2
polystyrene bottles in an incubator at 37ºC
and humidified with a gaseous mixture of
95% air and 5% carbon dioxide.
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Gas hypoxia
Each culture bottle was capped with a
silicone cork and sealed with paraffin. We
used two 30 x 7-mm needles to transfix the
cork to provide an access to infuse the gas-
eous mixture containing 95% nitrogen and
5% carbon dioxide. Three to 4 liters per
minute of this gaseous mixture were infused
for 30 min, reducing the partial oxygen pres-
sure (PaO2, 162 ± 10 mmHg) in the culture
medium (17). PaO2 was measured with a
potentiometric electrode in a blood gas ana-
lyzer. Cells were then harvested for the ex-
periments.
Drugs
Indomethacin (Sigma, St. Louis, MO,
USA) was used at two different concentra-
tions, 100 and 300 µM, for 72 h prior to the
gaseous hypoxia. Controls included cells
not treated with indomethacin or treated with
the vehicle (DMSO, 10 and 30 µL), sub-
jected or not to hypoxia. The cells were
studied immediately after hypoxia, with no
reperfusion.
Protocol of cell injury
Cell viability was determined by the ex-
clusion method using two fluorescent dyes.
After trypsinization the cells were resus-
pended in 1 mL PBS. A solution of acridine
orange (100 µg/mL) and ethidium bromide
(100 µg/mL) was added to the 10-µL cell
sample. Ethidium bromide and acridine or-
ange excite orange and green fluorescence,
respectively, when they are intermingled
within the DNA. Ethidium bromide is elimi-
nated when the plasma membrane is intact
and therefore only acridine orange crosses
the membrane, leading to green fluorescence.
A brilliant orange coloration is observed
when both ethidium bromide and acridine
orange are absorbed by the cells (17). Ap-
proximately 150 to 200 cells were counted
and considered to be viable when they were
stained green and nonviable when they were
stained orange. Results are reported as per-
cent viable cells.
Cell viability was also measured by lac-
tate dehydrogenase (LDH) leakage through
the membrane into the medium. This assay,
which strongly correlates with the number
of lysed cells, was based on the reduction of
nicotinamide-adenine dinucleotide (NAD)
to NADH by LDH (18). LDH activity in the
supernatant and in the cell homogenate was
determined by measuring absorbance at 340
nm. Cytotoxicity was reported as percent
LDH released, corresponding to the ratio
between LDH activity in the supernatant and
total LDH activity. Throughout the entire
reading, the samples were maintained under
shaking and at a constant temperature of
25ºC.
mRNA expression
RNA was extracted from endothelial cells
exposed or not to gaseous hypoxia, and pre-
treated or not with indomethacin, using TRI-
REAGENT™ (Sigma), according to the
manufacturer’s protocol. RNA concentra-
tion was quantified with a spectrophotom-
eter. Samples with an A260/A280 ratio above
1.7 were considered to be free of DNA and
proteins. mRNA was reverse transcribed into
complementary DNA using expand reverse
polymerase (Boehringer Mannheim, East
Sussex, UK). The mRNA of COX-1, COX-
2, HO-1, HIF-1α, RANTES, and ß-actin
was amplified using specific primer se-
quences: COX-1 280 bp, sense: 5' GGT GGA
GGT AGG AAC TTT GAC 3', anti-sense: 5'
GAG CCC CCA TCT CTA TCA TAC 3';
COX-2: 448 bp, sense: 5' CAT TGA AGA
CCA GGA GTA 3', anti-sense: 5' CCA GTA
TTG AGG AGA ACA 3'; HO-1: 102 bp,
sense: 5' TGA CAC CTG AGG TCA AGC
ACA 3', anti-sense: 5' GTT CGT CTG TCA
GCA CCT G 3'; HIF-1α: 96 bp, sense: 5'
ATT GCA GCA ACC AGG TGA CTG 3',
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anti-sense: 5' GCA GCT TGC ATG CTA
ATT CGG 3'; RANTES: 205 bp, sense: 5'
CCC ATA TGG CTC GGA CAC CA 3',
anti-sense: 5' CTA GCT CAT CTC CAA
ATA GTT GAT 3', and ß-actin: 375 bp,
sense: 5' CGT GAC ATT AAG GAG AAG
CTG TGC 3', anti-sense: 5' CTC AGG AGG
AGC AAT GAT CTT GAT 3'. PCR was
performed with 5 µL cDNA in a 25-µL reac-
tion volume using PCR Master Mix™ (Pro-
mega, Southampton, UK). The PCR condi-
tions consisted of 35 cycles of denaturation
at 95°C (1 min), annealing at 55°C for 1.5
min and extension at 72°C for 2 min, fol-
lowed by a final incubation of 72°C for 10
min. These conditions were applied to all
primers. PCR products were run on 1.5%
agarose gel and stained with a fluorescent
dye (Syber Green I, Molecular Probes,
Carlsbald, CA, USA). The gels were scanned
to estimate relative band intensity using a
Storm scanner and Image Quant 4.0 soft-
ware (Molecular Dynamics, Sunnyvale, CA,
USA). Semi-quantitative RNA estimation
was carried out with ß-actin as an internal
control. The results are reported as the ratio
of arbitrary units of the band densities of the
gene and of the internal control (ß-actin).
Statistical analysis
Data are reported as means ± SD or as
percent increase unless otherwise stated. PCR
products were analyzed by densitometry and
semi-quantified, and the results are shown in
histograms. Each gene transcript was nor-
malized to ß-actin mRNA values and was
reported as median and ranges. Percent in-
crease and a decrease in mRNA expression
were calculated according to basal expres-
sion used as a reference level. Parametric
and non-parametric tests were used for com-
parison among groups, with the level of
significance set at P < 0.05.
Results
Cell injury protocol
Gas insufflation induced a reduction of
45.12 ± 5.85% in PaO2. Endothelial cells
subjected to gaseous hypoxia showed a
higher level of LDH release (35.96 ± 11.64
vs 22.19 ± 9.65%, P = 0.002) and low viabil-
ity (percentage of viable cells: 73.1 ± 2.73
vs 91.2 ± 0.95%, P < 0.05) compared to
those that remained in a non-hypoxic state.
Under normoxic conditions, vehicle and in-
domethacin treatments alone did not alter
cell viability or LDH release (viability: 88.9
± 1.8 and 92.5 ± 5.3%, respectively; LDH
release: 16.4 ± 3.4 and 18.7 ± 2.8%, respec-
tively).
Gene transcript analyses
Immortalized endothelial cells expressed
COX-2 mRNA under basal conditions, al-
though at a lower level compared to COX-1
mRNA expression, 0.38 (0.179-0.95) and
0.67 (0.06-1.14), respectively. After hypoxia,
we observed mRNA in the same proportion
of up-regulation of both COX isoforms (27
and 29%) compared to pre-hypoxic levels
(COX-2: 0.53, 0.29-0.80; COX-1: 0.86,
0.282-1.13). Indomethacin was then added
to the culture at two different concentra-
tions; 100 µM indomethacin inhibited COX-
1 and COX-2 mRNA by 40 and 29%, re-
spectively, whereas a higher concentration
of 300 µM caused 100 and 99% inhibition,
Figure 1. COX-1/ß-actin mRNA
ratios in control endothelial cells,
in endothelial cells subjected to
hypoxia and in cells pre-treated
with 100 and 300 µM indometh-
acin and subjected to hypoxia.
Data are reported as the median
of 14 independent experiments.
COX = cyclooxygenase. *P <
0.05 compared to hypoxia (no
indomethacin) (Mann-Whitney
U-test).
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respectively. The arbitrary units of mRNA
COX-1 and COX-2 normalized to ß-actin
mRNA levels were shown in Figures 1 and 2.
Effect of COX inhibition on endothelial cell
function
Once we had determined the best con-
centration to use associated with COX mRNA
inhibition, we evaluated its effect on cell
integrity. Prior treatment with 300 µM indo-
methacin improved the viability of cells sub-
jected to the hypoxic insult compared to
those treated with vehicle (percentage of
viable cells: 87.8 ± 2 vs 73.1 ± 2.73%, P =
0.015). Thus, the viability of vehicle-treated
cells subjected to hypoxia did not increase
(76.7 ± 3.8%).
Most striking, indomethacin (300 µM)
inhibited the expression of RANTES mRNA
that was up-regulated after hypoxia. Indo-
methacin-treated hypoxic endothelial cells
showed a lower chemokine expression than
cells pre-treated with vehicle (Figure 3).
The immortalized endothelial cells did
not express HO-1 mRNA at the basal level.
However, after 30 min of gaseous hypoxia,
HO-1 mRNA was highly up-regulated, show-
ing the pattern of a stress-inducible gene.
Indomethacin pre-treatment did not induce
HO-1 mRNA expression in those cells that
remained in a non-hypoxic state (data not
shown). Therefore, when it was added to
hypoxia-stressed endothelial cells, indometh-
acin significantly down-regulated HO-1
mRNA expression, mainly at a higher con-
centration (Figure 4A). The down-regula-
tion of the HO-1 transcript was simulta-
neous to the decrease in COX-2 mRNA.
Since hypoxia-induced HO-1 expression is
mainly regulated by HIF-1α, we then inves-
tigated its mRNA under similar conditions.
Similar to what was just described, HIF-1α
was markedly up-regulated after hypoxia
and down-regulated by prior indomethacin
treatment, namely at a concentration of 300
µM (Figure 4, panel B).
Figure 2. COX-2/ß-actin mRNA
in control endothelial cells, in
endothelial cells subjected to
hypoxia and in cells pre-treated
with 100 and 300 µM indometh-
acin and subjected to hypoxia.
COX = cyclooxygenase. Data
are reported as the median of 14
independent experiments. *P <
0.05 compared to hypoxia (no
indomethacin) (Mann-Whitney
U-test).
Figure 3. Typical gel of RANTES and ß-actin mRNA expressed by endothelial cells treated
with 300 µM indomethacin or vehicle and subjected to hypoxia (panel A) and the correspond-
ing values obtained by gel densitometry (panel B). RANTES and ß-actin amplified a fragment
of 205 and 375 bp, respectively. Data are reported as the median of 4 independent experi-
ments. RANTES = regulated upon activation, normal T cell expressed and secreted mol-
ecule. P < 0.05 for indomethacin-treated cells vs vehicle-treated cells (Mann-Whitney U-test).
Discussion
Endothelial cells play a central role in the
inflammatory response to ischemic injury.
They can be either a target of the aggression
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kocytes, driving them into the tissue. Impor-
tant mediators of this cascade are the ROS,
which are produced during ischemia and
released after reperfusion, due in part to the
cleavage of arachidonic acid by COX-1 and
COX-2 (8,19,20). Although COX-2 is also
expressed in response to several physiologi-
cal stimuli, it is the key molecule in inflam-
mation. COX-2 up-regulation is a hallmark
of IRI (10,12). Moreover, many investiga-
tors have demonstrated the importance of
the blockade of the COX pathway in pro-
moting better organ function in ischemic
injuries. Indeed, we have demonstrated that
animals treated with indomethacin were pro-
tected against IRI in a mouse model of acute
renal failure (11,12).
When the endothelium is facing an in-
sult, this barrier is able to orchestrate a pro-
tective cellular response that ultimately in-
volves the inducible expression of genes
with anti-inflammatory and anti-apoptotic
properties, such as bcl-2 and HO-1. Thus,
the balance between aggression and intrin-
sic cytoprotection ultimately determines the
outcome of the injured tissue or organ.
Here, we describe in an in vitro model
that the inhibition of COX-1 and COX-2
mRNA expression by a specific, although
non-selective drug, improved endothelial cell
function after gaseous hypoxia. Indometh-
acin treatment was associated with an en-
hancement of endothelial cell viability con-
current with COX mRNA inhibition. Indeed,
we observed that once the noxious stimuli
presented by the COXs were prevented, the
expression of HO-1 was also largely inhib-
ited. Additionally, we observed that indo-
methacin positively down-regulated the
mRNA of the transcriptional factor HIF-1α
and the RANTES chemokines.
Recent data suggest that endothelial cells
are highly specialized in acquiring a protec-
tive phenotype when facing a stressor. The
role of the so-called “protective genes” has
been well documented in recent years. Spe-
cifically, HO-1 represents one of the best
Figure 4. HO-1 (panel A) and HIF-1α (panel B) mRNA expressed by control
endothelial cells, by endothelial cells subjected to hypoxia and by cells pre-treated
with 100 and 300 µM indomethacin and subjected to hypoxia. Gene transcripts
were normalized to ß-actin. HO-1 = heme oxygenase-1; HIF-1α = hypoxia-inducible
factor-1α. Data are reported as the median of 8 independent experiments. *P < 0.05
compared to respective hypoxia (Mann-Whitney U-test).
or a mediator of an active protective process
that intends to limit the hypoxic damage.
Endothelial cell activation leads to pro-in-
flammatory cytokine and chemokine pro-
duction, which promotes activation of leu-
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examples of this gene family. HO-1 acts as an
anti-apoptotic, an anti-inflammatory and an
anti-proliferative molecule through its end
products carbon monoxide, biliverdin and free
iron (21). Its role in promoting better organ
function has been demonstrated in different
animal and human models (22, 23).
Interestingly, the relationship between
HO-1 and COX is just being clarified. Prior
up-regulation of HO-1 in endothelial cells
has been associated with protection against
apoptosis and cellular dysfunction (24-26).
However, once the insult is established, cel-
lular protection can also be achieved by
limiting COX-2 production via specific drug
inhibitors. The influence of COX-2 on the
suppression or enhancement of HO-1 ex-
pression is of considerable physiological
importance.
HO-1 is up-regulated following IRI and
endotoxemia (20). In these models, COX-2
is also up-regulated. Indeed, Ejima and
Perrella (27) demonstrated that in the ab-
sence of COX-2 there is no up-regulation of
HO-1 following LPS treatment in mice, dem-
onstrating that COX is actually the stimulus
for HO-1 expression. In contrast, but in agree-
ment with these data, prior induction of HO-
1 by gene therapy or by chemical products,
such as cobalt protoporphyrin, abrogates
COX-2 expression in various inflammatory
models (28-30). Similarly, treatment with a
COX-2 inhibitor is associated with HO-1
up-regulation (31). Furthermore, it has been
reported that arachidonic acid, a substrate of
COX, induces HO-1 activity (32), although
the mechanism is not totally clear. Finally,
few recent data incriminated ROS produc-
tion, induced by COX, in promoting HO-1
expression (33). In this respect, COX inhibi-
tion is in fact associated with HO-1 repres-
sion, making this relationship controversial.
In the present study, we showed that
COX inhibition was indeed followed by an
improvement in cell integrity and a less pro-
inflammatory phenotype, taking into account
the repression of RANTES mRNA. We be-
lieved that, once we had prevented the po-
tential harm embodied by those molecules,
HO-1 was not induced, as the danger signal
was no longer present. Data from Takeda
and colleagues (33) agree with our results.
Following glucose deprivation, cardiac fi-
broblasts up-regulated HO-1 and COX-2,
which were then inhibited by N-acetylcys-
teine (33).
We showed that HO-1 was induced by
hypoxic stress and that its expression was
negatively regulated by blockade of the COX
pathway. The beneficial effect of indometh-
acin seems to involve down-modulation of
chemokine production. The possibility of
limiting the inflammatory cascade that fol-
lows IRI has new implications for those
patients at high risk of ischemic events. Early
inhibition of the COX pathway is demon-
strated to be a useful tool in improving organ
function after ischemic damage.
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